JonesTrading Initiates Coverage on Sensei Biotherapeutics (NASDAQ:FTH)

Investment analysts at JonesTrading assumed coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a research note issued to investors on Tuesday,Benzinga reports. The firm set a “buy” rating and a $55.00 price target on the stock. JonesTrading’s target price would indicate a potential upside of 131.34% from the company’s previous close.

Several other brokerages have also recently weighed in on FTH. Loop Capital set a $50.00 price objective on Sensei Biotherapeutics in a research note on Thursday, May 28th. Weiss Ratings assumed coverage on Sensei Biotherapeutics in a report on Wednesday, June 17th. They issued a “sell (d-)” rating for the company. Robert W. Baird initiated coverage on Sensei Biotherapeutics in a report on Friday, June 26th. They set an “outperform” rating and a $57.00 price target on the stock. Citizens Jmp initiated coverage on Sensei Biotherapeutics in a research report on Monday, July 20th. They issued an “outperform” rating and a $51.00 price target for the company. Finally, Oppenheimer started coverage on shares of Sensei Biotherapeutics in a research report on Tuesday, July 28th. They set an “outperform” rating and a $60.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $54.90.

Sensei Biotherapeutics Price Performance

NASDAQ FTH traded down $3.56 during trading on Tuesday, hitting $23.77. 344,921 shares of the stock traded hands, compared to its average volume of 200,596. The stock has a market capitalization of $31.91 million, a PE ratio of -0.17 and a beta of -0.26. Sensei Biotherapeutics has a 12-month low of $7.20 and a 12-month high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.04) by $4.42. On average, analysts anticipate that Sensei Biotherapeutics will post -16.61 EPS for the current fiscal year.

Insiders Place Their Bets

In other Sensei Biotherapeutics news, CEO Anand Kiran Parikh bought 2,806 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was acquired at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the completion of the transaction, the chief executive officer owned 764,234 shares in the company, valued at $15,101,263.84. This trade represents a 0.37% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder James Peyer sold 25,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00. Following the sale, the insider directly owned 130,142 shares of the company’s stock, valued at $2,605,442.84. This represents a 16.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have acquired a total of 49,494 shares of company stock worth $1,188,822 over the last quarter. Company insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Sensei Biotherapeutics

A number of institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC boosted its stake in shares of Sensei Biotherapeutics by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock worth $123,000 after buying an additional 1,100 shares during the last quarter. Stempoint Capital LP acquired a new position in Sensei Biotherapeutics in the first quarter valued at approximately $4,188,000. Bank of America Corp DE boosted its position in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Finally, Vivo Capital LLC purchased a new stake in Sensei Biotherapeutics in the 1st quarter worth approximately $22,758,000. Hedge funds and other institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.